Effect of Sacubitril/Valsartan on the recurrence of atrial fibrillation after catheter ablation

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1061230045

Enrollment

200

Registered

2023-08-08

Start date

2024-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation persistent atrial fibrillation, catheter ablation

Interventions

Sacubitril/Valsartan(SV) or Valsartan(V) should be started between the day before and the day after undergoing catheter ablation. The initial dose of SV is 100mg, V is 40mg once a day. The SV and V do

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who are aged 20 years and older, and younger than 80 years. 2. Patients who are scheduled to undergo catheter ablation for persistent atrial fibrillation at the first time, and with hypertension. 3. Patients who give written informed consents before treatment.

Exclusion criteria

Exclusion criteria: 1. NYHA class4 2. Hyperthyroidism or hypothyroidism 3. Moderate or severe mitral disease 4. Severe renal dysfunction(eGFR<30ml/min/1.73m2) 5. The presence of a prosthetic heart valve 6. Presence of thrombus in left atrial appendage 7. History of hypersensitivity to Sacubitril/Valsartan or Valsartan 8. History of angioedema due to angiotensin 2 receptor antagonist or angiotensin convertinf enzyme inhibitor , Hereditary/Aquired Angioedema, or idiopathic angioedema 9. Administration of aliskiren fumarate to diabetes mellitus 10. Severe hepatic dysfunction(Child Pugh C) 11. Pregnant, unwilling to practice contraception during the study, or lactation female 12. Patients who are participating, or intend to participate in other clinical trials during the study 13. Patients who obstruct, bind or confuse the specific assessment about protcol in the study 14. Principal Investigator involving in the study, or employees of the participating medical center, or their family

Design outcomes

Primary

Measure	Time frame
Reccurence rate of atrial fibrillation 12 months after catheter ablation	—

Secondary

Measure	Time frame
Supraventricular arrhythmias lasting >24 hours Left atrial diameter and left atrial volume, peak atrial longitudinal strain	—

Contacts

Public ContactNaoto Oguri

Hiroshima University Hospital

d216209@hiroshima-u.ac.jp+81-82-257-5540

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026